Table 2 Laboratory tests, chest imaging, and nucleic acid testing of suspected cases of COVID-19
From: Differential diagnosis for suspected cases of coronavirus disease 2019: a retrospective study
Confirmed COVID-19 group n = 17 | COVID-19-negative group n = 51 | P value | |
|---|---|---|---|
White blood cell count, mean (SD), ×109/L | 5.27 ± 2.08 | 6.73 ± 1.94 | 0.010 |
< 4, n (%) | 5 (29.4%) | 2 (3.9%) | 0.003 |
4–10, n (%) | 12 (70.6%) | 47 (92.2%) | 0.023 |
> 10, n (%) | 0 | 2 (3.9%) | NA |
Lymphocyte count, mean (SD), ×109/L | 1.35 ± 0.83 | 1.63 ± 0.81 | 0.224 |
< 1.1, n (%) | 8 (47.1%) | 13 (25.5%) | 0.096 |
≥ 1.1, n (%) | 9 (52.9%) | 38 (74.5%) | |
Hemoglobin concentration, mean (SD), (g//L) | 135.18 ± 17.02 | 138.66 ± 20.33 | 0.528 |
< 120, n (%) | 3 (17.6%) | 7 (13.7%) | 0.693 |
≥ 120, n (%) | 14 (82.4%) | 44 (86.3%) | |
Platelet count, mean (SD), (×109/L) | 198.41 ± 92.02 | 217.52 ± 72.42 | 0.384 |
< 100, n (%) | 1 (5.9%) | 2 (2.9%) | NA |
≥ 100, n (%) | 16 (94.1%) | 49 (96.1%) | |
C-reactive protein, mean (SD), (mg/L) | 29.27 ± 31.30 | 17.25 ± 23.31 | 0.097 |
Chest CT, n (%) | |||
Ground-glass opacities | 14 (82.4%) | 16 (31.4%) | 0.0002 |
Consolidation | 7 (41.2%) | 9 (17.6%) | 0.048 |
Patchy shadows | 13 (76.5%) | 22 (43.1%) | 0.017 |
Grid-like images | 3 (17.6%) | 2 (3.9%) | |
Bronchial wall thickening | 0 | 5 (9.8) | NA |
Reversed halo sign | 0 | 1 (2.0) | NA |
Bilateral pulmonary involvement | 14 (82.4%) | 8 (15.7%) | < 0.001 |
SARS-CoV-2 nucleic acid testing, n (%) | |||
Positive in the first test | 13 (76.5%) | 0 | |
Positive in the second test | 3 (17.6%) | 0 | |
Weak positive in the first test | 1 (5.9%) | 0 | |
Suspected positive in the first test | 1 (5.9%) | 1 (2.0%) | |
Multiplex PCR, n (%) | |||
Influenza A | 0 | 2 (3.9%) | |
Influenza B | 0 | 3 (5.9%) | |
Adenovirus | 0 | 2 (3.9%) | |
Chlamydia pneumoniae | 0 | 2 (3.9%) | |
Mycoplasma pneumoniae | 0 | 7 (13.7%) | |